ArticleCells2022
Human Platelet-Rich Plasma Facilitates Angiogenesis to Restore Impaired Uterine Environments with Asherman's Syndrome for Embryo Implantation and Following Pregnancy in Mice.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review.Human reproduction update · 2024Pooled it
- Platelet-rich plasma as an adjuvant therapy for intrauterine adhesions: a narrative review of mechanisms, clinical efficacy and combination strategies.Annals of medicine · 2026Review
- A sequential and synergistic release sacrificial microgels scaffold for endometrial niche reprogramming and fertility restoration.Materials today. Bio · 2026Article
- Research progress on blood therapy for anti-aging.Journal of advanced research · 2026Review
- Effect of intrauterine administration of platelet-rich plasma two days before timed artificial insemination in dairy cows on endometrial thickness and conception rate.The Journal of veterinary medical science · 2026Article
- Integrating platelet-rich plasma therapy into nursing practice: a review of biological mechanisms and clinical applications.Frontiers in bioengineering and biotechnology · 2026Review
- Regenerating the uterus: translational advances in endometrial bioengineering and immunotherapeutics.Seminars in immunopathology · 2025Review
- Enhancing exosome stability and delivery with natural polymers to prevent intrauterine adhesions and promote endometrial regeneration: a review.Journal of nanobiotechnology · 2025Review
- The use of autologous platelet-rich plasma in embryo culture to obtain high-quality embryos.Scientific reports · 2025Article
- The application of tissue engineering strategies for uterine regeneration.Materials today. Bio · 2025Review
- Review
- The Effect of Autologous Platelet Rich Plasma on Endometrial Receptivity: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Rodent models of functional hypothalamic amenorrhea: a systematic scoping review.Frontiers in endocrinology · 2025Article
- The Clinical Application of Platelet-Rich Plasma in the Female Reproductive System: A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Value of Intrauterine Autologous Platelet-Rich Plasma Therapy on Endometrial Receptivity: A Literature Review.Current medical science · 2023Review
- Research progress on the STAT signaling pathway in pregnancy and pregnancy-associated disorders.Frontiers in immunology · 2023Review
- Human umbilical cord platelet-rich plasma to treat endometrial pathologies: methodology, composition and pre-clinical models.Human reproduction open · 2023Article
- Epigenetics, ovarian cell plasticity, and platelet-rich plasma: Mechanistic theories.Reproduction & fertility · 2022Article
- Platelet-rich plasma treatment in patients with refractory thin endometrium and recurrent implantation failure: A comprehensive review.Clinical and experimental reproductive medicine · 2022Article
- Recurrent implantation failure: A comprehensive summary from etiology to treatment.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asherman's syndrome (AS) is caused by intrauterine adhesions and inactive endometrium from repeated curettage of the uterine endometrium. AS is a major cause of recurrent implantation failure and miscarriage and is very difficult to treat because of the poor recovery of endometrial basal cells. Platelet-rich plasma (PRP) has abundant growth factors that may induce angiogenesis and cell proliferation. Here, we demonstrate that human PRP (hPRP) significantly enhances angiogenesis to restore embryo implantation, leading to successful pregnancy in mice with AS. In mice with AS, hPRP treatment considerably reduced the expression of fibrosis markers and alleviated oligo/amenorrhea phenotypes. Mice with AS did not produce any pups, but the hPRP therapy restored their infertility. AS-induced abnormalities, such as aberrantly delayed embryo implantation and intrauterine growth retardation, were considerably eliminated by hPRP. Furthermore, hPRP significantly promoted not only the elevation of various angiogenic factors, but also the migration of endometrial stromal cells. It also increased the phosphorylation of STAT3, a critical mediator of wound healing, and the expression of tissue remodeling genes in a fibrotic uterus. PRP could be a promising therapeutic strategy to promote angiogenesis and reduce fibrosis in impaired uterine environments, leading to successful embryo implantation for better clinical outcomes in patients with AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.